Immix Biopharma announced that the European Commission has granted orphan drug designation to NXC-201 for the treatment of AL Amyloidosis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMX:
- Immix Biopharma Announces New Offering, Sparks Investor Interest
- Immix Biopharma Signs Definitive $15M Titan Partnership Deal
- Immix Biopharma 5.5M share priced at $2.71
- Immix Biopharma Suspends Stock Offering Pending New Prospectus
- Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
